Infusion set with improved bore configuration

Information

  • Patent Grant
  • 8920381
  • Patent Number
    8,920,381
  • Date Filed
    Friday, April 12, 2013
    11 years ago
  • Date Issued
    Tuesday, December 30, 2014
    9 years ago
Abstract
An infusion set for use with a fluid infusion device is provided. The infusion set can include a mount including a projection having a bore. The projection can be surrounded at least partially by a recess defined through a surface of the mount, and the mount can include at least one rib that spans the recess. The infusion set can include a fluid outlet coupled to at least a portion of the bore of the projection and a coupling device to couple the infusion set to a user. The coupling device can be coupled to the surface and the at least one rib of the mount.
Description
TECHNICAL FIELD

Embodiments of the subject matter described herein relate generally to fluid infusion devices for delivering a medication fluid to the body of a user. More particularly, embodiments of the subject matter relate to systems for an insulin infusion set having an improved bore configuration for use with a fluid infusion device.


BACKGROUND

Certain diseases or conditions may be treated, according to modern medical techniques, by delivering a medication or other substance to the body of a user, either in a continuous manner or at particular times or time intervals within an overall time period. For example, diabetes is commonly treated by delivering defined amounts of insulin to the user at appropriate times. Some common modes of providing insulin therapy to a user include delivery of insulin through manually operated syringes and insulin pens. Other modern systems employ programmable fluid infusion devices (e.g., insulin pumps) to deliver controlled amounts of insulin to a user.


A fluid infusion device suitable for use as an insulin pump may be realized as an external device or an implantable device, which is surgically implanted into the body of the user. External fluid infusion devices include devices designed for use in a generally stationary location (for example, in a hospital or clinic), and devices configured for ambulatory or portable use (to be carried by a user). External fluid infusion devices may establish a fluid flow path from a fluid reservoir to the user via, for example, a hollow tubing. The hollow tubing may be connected to a hollow fluid delivery needle that is designed to pierce the user's skin to deliver an infusion medium to the body. Alternatively, the hollow tubing may be connected directly to the user's body through a cannula or set of micro-needles. In order to ensure proper fluid delivery, the hollow tubing needs to be properly coupled to the user's body.


Accordingly, it is desirable to provide an infusion set having an improved bore configuration for coupling of a hollow tubing in communication with a fluid infusion device to a user's body to ensure proper insulin delivery. Furthermore, other desirable features and characteristics will become apparent from the subsequent detailed description and the appended claims, taken in conjunction with the accompanying drawings and the foregoing technical field and background.


BRIEF SUMMARY

According to various exemplary embodiments, an infusion set for use with a fluid infusion device is provided. The infusion set can comprise a mount including a projection having a bore. The projection can be surrounded at least partially by a recess defined through a surface of the mount, and the mount can include at least one rib that spans the recess. The infusion set can include a fluid outlet coupled to at least a portion of the bore of the projection and a coupling device to couple the infusion set to a user. The coupling device can be coupled to the surface and the at least one rib of the mount.


Also provided according to various embodiments is an infusion set for use with a fluid infusion device. The infusion set can include a connector to fluidly couple the fluid infusion device to the infusion set. The infusion set can also include a mount having a distal end coupled to the connector and a proximal end. The mount can include a projection having a bore that extends along an axis. The proximal end can include a plurality of ribs that extend from a surface of the proximal end to the projection. The plurality of ribs can be arranged to lie in a plane transverse to the axis. The infusion set can include a fluid outlet coupled to at least a portion of the bore of the mount to be in fluid communication with the fluid infusion device through the connector. The infusion set can also comprise a coupling device to couple the infusion set to a user. The coupling device can be coupled to the surface and each of the plurality of spaced apart ribs of the proximal end.


This summary is provided to introduce a selection of concepts in a simplified form that are further described below in the detailed description. This summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used as an aid in determining the scope of the claimed subject matter.





BRIEF DESCRIPTION OF THE DRAWINGS

A more complete understanding of the subject matter may be derived by referring to the detailed description and claims when considered in conjunction with the following figures, wherein like reference numbers refer to similar elements throughout the figures.



FIG. 1 is a perspective view of an exemplary embodiment of a fluid infusion device including an infusion set according to various teachings of the present disclosure;



FIG. 2 is a side view of the exemplary infusion set of FIG. 1;



FIG. 3 is a partially exploded view of the exemplary infusion set of FIG. 1; and



FIG. 4 is an environmental cross-sectional view of the exemplary infusion set of FIG. 1, taken along line 4-4 of FIG. 1.





DETAILED DESCRIPTION

The following detailed description is merely illustrative in nature and is not intended to limit the embodiments of the subject matter or the application and uses of such embodiments. As used herein, the word “exemplary” means “serving as an example, instance, or illustration.” Any implementation described herein as exemplary is not necessarily to be construed as preferred or advantageous over other implementations. Furthermore, there is no intention to be bound by any expressed or implied theory presented in the preceding technical field, background, brief summary or the following detailed description.


Certain terminology may be used in the following description for the purpose of reference only, and thus are not intended to be limiting. For example, terms such as “top”, “bottom”, “upper”, “lower”, “above”, and “below” could be used to refer to directions in the drawings to which reference is made. Terms such as “front”, “back”, “rear”, “side”, “outboard”, and “inboard” could be used to describe the orientation and/or location of portions of the component within a consistent but arbitrary frame of reference which is made clear by reference to the text and the associated drawings describing the component under discussion. Such terminology may include the words specifically mentioned above, derivatives thereof, and words of similar import. Similarly, the terms “first”, “second”, and other such numerical terms referring to structures do not imply a sequence or order unless clearly indicated by the context.


The following description relates to a fluid infusion device of the type used to treat a medical condition of a user. The infusion device can be used for infusing fluid into the body of a user. The non-limiting examples described below relate to a medical device used to treat diabetes (more specifically, an insulin pump), although embodiments of the disclosed subject matter are not so limited. Accordingly, the infused medication fluid is insulin in certain embodiments. In alternative embodiments, however, many other fluids may be administered through infusion such as, but not limited to, disease treatments, drugs to treat pulmonary hypertension, iron chelation drugs, pain medications, anti-cancer treatments, medications, vitamins, hormones, or the like. For the sake of brevity, conventional features and characteristics related to infusion system operation, insulin pump and/or infusion set operation, fluid reservoirs, and fluid syringes may not be described in detail here. Examples of infusion pumps and/or related pump drive systems used to administer insulin and other medications may be of the type described in, but not limited to: U.S. Patent Publication Nos. 2009/0299290 and 2008/0269687; U.S. Pat. Nos. 4,562,751; 4,678,408; 4,685,903; 5,080,653; 5,505,709; 5,097,122; 6,485,465; 6,554,798; 6,558,351; 6,659,980; 6,752,787; 6,817,990; 6,932,584; 7,621,893; 7,828,764; and 7,905,868; which are each incorporated by reference herein.



FIG. 1 is a perspective view of an exemplary embodiment of a fluid infusion system 100. The fluid infusion system 100 includes two main components: a fluid infusion device 102 (e.g., an insulin pump) and an infusion set component 104, which can be coupled to the fluid infusion device 102 as depicted in FIG. 1. The infusion set component 104 can include, without limitation: a tube 110, an infusion unit 112 and a connector assembly 114. The infusion unit 112 can be coupled to a first end 116 of the tube 110 and the connector assembly 114 can be coupled to a second end 118 of the tube 110. The fluid infusion device 102 can be carried or worn by the user, and the infusion set component 104 terminates at the infusion unit 112 such that the fluid infusion device 102 can deliver fluid to the body of the user via the tube 110. Thus, the infusion unit 112 can be coupled to the body of the user, as described in more detail below. The fluid infusion device 102 may leverage a number of conventional features, components, elements, and characteristics of existing fluid infusion devices. For example, the fluid infusion device 102 may incorporate some of the features, components, elements, and/or characteristics described in U.S. Pat. Nos. 6,485,465 and 7,621,893, the relevant content of which is incorporated by reference herein. It should be noted that the fluid infusion device 102 illustrated herein is merely exemplary, as any suitable fluid infusion device can be employed with the infusion set component 104. Furthermore, the techniques described herein for coupling the infusion unit 112 to the body of a user can be employed with other devices, such as an analyte monitoring device coupled to the body of a user. Thus, the following description is merely exemplary and is not intended to limit the scope of the appended claims.


The fluid infusion device 102 accommodates a fluid reservoir (hidden from view in FIG. 1) for the fluid to be delivered to the user. The tube 110 represents the fluid flow path that couples the fluid reservoir to the infusion unit 112. When installed as depicted in FIG. 1, the tube 110 extends from the fluid infusion device 102 to the infusion unit 112, which in turn provides a fluid pathway to the body of the user. For the illustrated embodiment, the connector assembly 114 is realized as a removable reservoir cap 120 (or fitting) that is suitably sized and configured to accommodate replacement of fluid reservoirs (which are typically disposable) as needed. In this regard, the reservoir cap 120 is designed to accommodate the fluid path from the fluid reservoir to the tube 110.


With reference to FIG. 2, a schematic side view of the infusion unit 112 is shown. In one example, the infusion unit 112 can include a connector 122, a mount 124, a coupling device 126 and a fluid outlet 128. The connector 122 can be coupled to the first end 116 of the tube 110 and to the mount 124. The connector 122 can have any desired shape and configuration to facilitate fluid flow from the tube 110 through the infusion unit 112. In one example, the connector 122 can be substantially annular and can define a throughbore 132 for coupling the connector 122 to the mount 124. The connector 122 can also define a passageway 134, which can enable the first end 116 of the tube 110 to pass through the connector 122. The tube 110 can be coupled to the connector 122 through any suitable technique, including, but not limited to, press-fit, adhesives, etc. The passageway 134 can be in communication with a passageway 136 of the mount 124 to enable the tube 110 to be fluidly coupled to the fluid outlet 128.


With continued reference to FIG. 2, the mount 124 can include a first or distal end 138, a second or proximal end 140, the passageway 136, an internal projection 142 and an internal recess 144. In one example, the connector 122 can be coupled to the distal end 138 and the coupling device 126 can be coupled to the proximal end 140. Generally, the distal end 138 can be sized so as to be received within the throughbore 132 of the connector 122. The distal end 138 of the mount 124 can be coupled to the connector 122 via any suitable technique, including, but not limited to, a press-fit, snap-fit, etc. The distal end 138 can have any desired shape that can cooperate with the connector 122, and in one example, can be substantially cylindrical.


The proximal end 140 can be coupled to the distal end 138. The proximal end 140 can be substantially annular, and can have a diameter, which can be greater than a diameter of the distal end 138. The proximal end 140 can have a height along an axis A of the infusion unit 112, which can be less than a height of the distal end 138 defined along the axis A. In one example, with reference to FIG. 3, the proximal end 140 can have at least one or a plurality of ribs 146. For example, the proximal end 140 can include about eight ribs. The ribs 146 can span the internal recess 144, to couple or connect the internal projection 142 with a surface 148 of the proximal end 140. In one example, the ribs 146 can be arranged at substantially evenly spaced intervals about a perimeter or circumference of the internal projection 142, however, the ribs 146 could be arranged so as to be spaced at different intervals or distances from each other about the perimeter of the internal projection 142. The ribs 146 can provide structural support to the internal projection 142, which can aid in maintaining the position of the fluid outlet 128 in the body of the user. In this regard, the ribs 146 can stiffen the internal projection 142, which can receive the fluid outlet 128 therethrough, and thereby the ribs 146 can aid in ensuring the fluid outlet 128 remains positioned along the axis A even with relative movement between the infusion unit 112 and the body of the user.


In one example, the ribs 146 can be substantially rectangular, however, the ribs 146 can have any desired shape. The ribs 146 can generally lie in a plane that is transverse to the axis A of the infusion unit 112, and can be substantially symmetric with respect to the axis A. In one example, the ribs 146 can extend radially from the axis A. The ribs 146 can have a width W that can be sized to enable a portion of the coupling device 126 to be coupled to the mount 124 so that the coupling device 126 is positioned adjacent to the internal projection 142. Generally, it is desirable to position the coupling device 126 as close to the internal projection 142 as possible to assist in maintaining the location of the fluid outlet 128 in the body of the user. It should be noted that the ribs 146 as described and illustrated herein are merely exemplary, and the proximal end 140 could have any number of ribs 146 in any desired shape to facilitate positioning a portion of the coupling device 126 adjacent to the internal projection 142. Furthermore, the proximal end 140 could include a wall that extends from the surface 148 to the internal projection 142 such that the internal recess 144 is substantially completely enclosed.


With reference to FIG. 2, the passageway 136 of the mount 124 can be in communication with a bore 150 defined through at least a portion of the internal projection 142. The bore 150 can be sized to receive at least a portion of the fluid outlet 128 to couple the fluid outlet 128 to the mount 124. In one example, the bore 150 can have a diameter D2 that can be substantially the same as a diameter D3 of the fluid outlet 128. For example, the diameter D2 of the bore 150 can be about 0.8 millimeters (mm) and the diameter D3 of the fluid outlet 128 can be substantially about 0.8 mm.


The internal projection 142 can be substantially cylindrical, and can extend from the distal end 138 to the proximal end 140. The internal projection 142 can generally extend through the internal recess 144 along the axis A of the infusion unit 112. The internal projection 142 can support and impart rigidity to the fluid outlet 128, and the ribs 146 can support and impart rigidity to the internal projection 142. The internal projection 142 can have a sidewall with a thickness selected such that the ribs 146 are substantially adjacent to the fluid outlet 128. By placing the ribs 146 closer to the fluid outlet 128, the coupling device 126 can be coupled closer to the fluid outlet 128, which can assist in maintaining the location of the fluid outlet 128 relative to the user during movement of the user.


The internal recess 144 can be defined through the surface 148 of the proximal end 140 and can extend through the proximal end 140 and a portion of the distal end 138. The internal recess 144 can provide the infusion unit 112 with flexibility such that the infusion unit 112 can move with the body of the user. The internal recess 144 can be substantially annular. It should be noted that the use of the internal recess 144 is merely exemplary, as the infusion unit 112 need not include the internal recess 144, if desired.


The coupling device 126 can couple the mount 124 to the body of the user. In one example, the coupling device 126 can comprise a mounting layer 152, an adhesive layer 154 and a backing 156. It should be noted that the mounting layer 152 and backing 156 are illustrated herein as having a nominal thickness, but that the mounting layer 152 and backing 156 could have any suitable thickness as necessary for the manufacture of the coupling device 126. The mounting layer 152 and adhesive layer 154 can be separately or integrally formed. The mounting layer 152 can couple or fixedly attach the adhesive layer 154 to the mount 124. The mounting layer 152 can be coupled or secured to the proximal end 140 of the mount 124 through any suitable technique, including, but not limited to, ultrasonic welding. Generally, the mounting layer 152 can be coupled to substantially all surface areas of the proximal end 140 of the mount 124. Thus, the mounting layer 152 can be coupled to the ribs 146 and the surface 148 of the proximal end 140. It should be noted that an end 142a of the internal projection 142 may not be coupled to the coupling device 126, if desired. In addition, while the mounting layer 152 is illustrated herein as being defined over substantially an entire surface of the coupling device 126, the mounting layer 152 can be coupled to just a portion of the surface of the adhesive layer 154. For example, the mounting layer 152 can be coupled to the adhesive layer 154 so as to extend over a portion of the adhesive layer 154 that corresponds with the portion of the coupling device 126 that is coupled to the mount 124. In other words, the mounting layer 152 can be sized to correspond to the size of the mount 124, and can have a radius that can be substantially smaller than a radius of the adhesive layer 154.


The adhesive layer 154 can enable the mount 124 to be removably coupled to the body of the user. It should be noted that the use of the adhesive layer 154 is merely exemplary, as any suitable technique could be used to removably couple the mount 124 to the user. The backing 156 can be coupled to at least a portion of the adhesive layer 154, and can be removed to facilitate coupling the coupling device 126 to the user, as is generally known in the art.


The fluid outlet 128 can be coupled to the tube 110, and can extend through the bore 150 of the internal projection 142. In one example, the fluid outlet 128 can comprise a portion of the first end 116 of the tube 110, however, the fluid outlet 128 can comprise a separate fluid conduit coupled to the first end 116 of the tube 110, including, but not limited to, a hollow needle, cannula, etc. Generally, the fluid outlet 128 can be composed of a suitable biocompatible material, such as a biocompatible polymer, however, the fluid outlet 128 can be composed of a suitable biocompatible metal or metal alloy, if desired. In the case of the fluid outlet 128 being composed of a biocompatible polymer, the ribs 146 and diameter D2 of the internal projection 142 can impart rigidity to the polymeric fluid outlet 128. At least a portion of the fluid outlet 128 can be received into a portion of the body of the user, to enable the fluid from the fluid infusion device 102 to flow into the body of the user. For example, with reference to FIG. 4, a first or proximal end 158 of the fluid outlet 128 can be received into a body B of the user, and a second or distal end 160 can be coupled to the first end 116 of the tube 110. The proximal end 158 can include a piercing tip 158a, however, the proximal end 158 can be atraumatic. In one example, the fluid outlet 128 can be substantially cylindrical, and can have the diameter D3, which can be substantially about equal to the diameter D2 of the bore 150. The fluid outlet 128 can be coupled to the mount 124 through any suitable technique, including, but not limited to, press-fitting, adhesives, etc.


In order to assemble the infusion unit 112, with reference to FIGS. 2 and 4, the coupling device 126 can be coupled to the mount 124. Then, the tube 110 can be coupled to the fluid outlet 128, and then coupled to or inserted through the passageway 134 of the connector 122, passageway 136 of the mount 124 and the bore 150. In one example, with the tube 110 in communication with the infusion unit 112, the tube 110 can be coupled to the fluid infusion device 102. Then, the infusion unit 112 can be coupled to the body B of the user (FIG. 4). For example, the backing 156 of the coupling device 126 can be removed to expose the adhesive 152 (FIG. 2). Then, the infusion unit 112 can be coupled or pressed onto the body B of the user, so that at least a portion of the fluid outlet 128 extends into the body B of the user, and the mount is removably coupled to the user via the coupling device 126 (FIG. 4). With the infusion unit 112 coupled to the user, fluid from the fluid reservoir of the fluid infusion device 102 can flow through the infusion unit 112 into the body B of the user.


In addition, by providing the bore 150 with the diameter D2 about substantially the same as the diameter D3 of the fluid outlet 128, the internal projection 142 can impart stability and reinforcement to the fluid outlet 128. This can ensure that the fluid outlet 128 remains disposed substantially along the axis A of the infusion unit 112 during movement of the user relative to the infusion unit 112, such as when the user is sleeping, for example. Further, by coupling the coupling device 126 to the ribs 146, which are adjacent to the bore 150, the infusion unit 112 is further secured to the user to ensure that the fluid outlet 128 remains disposed substantially along the axis A of the infusion unit 112 during movement of the user relative to the infusion unit 112.


While at least one exemplary embodiment has been presented in the foregoing detailed description, it should be appreciated that a vast number of variations exist. It should also be appreciated that the exemplary embodiment or embodiments described herein are not intended to limit the scope, applicability, or configuration of the claimed subject matter in any way. Rather, the foregoing detailed description will provide those skilled in the art with a convenient road map for implementing the described embodiment or embodiments. It should be understood that various changes can be made in the function and arrangement of elements without departing from the scope defined by the claims, which includes known equivalents and foreseeable equivalents at the time of filing this patent application.

Claims
  • 1. An infusion set for use with a fluid infusion device, comprising: a mount having a first end opposite a second end, the mount including an internal projection having a bore, the internal projection extending from the first end to the second end within the mount, the internal projection surrounded at least partially by an internal recess defined through a surface of the second end of the mount, the second end of the mount including at least one rib that spans the internal recess;a fluid outlet coupled to at least a portion of the bore of the internal projection; anda coupling device to couple the infusion set to a user, the coupling device coupled to the surface and the at least one rib of the second end of the mount.
  • 2. The infusion set of claim 1, further comprising: a connector to fluidly couple the fluid infusion device to the infusion set,wherein the connector is coupled to the first end of the mount to fluidly couple the fluid outlet with the fluid infusion device.
  • 3. The infusion set of claim 1, wherein the at least one rib further comprises a plurality of ribs.
  • 4. The infusion set of claim 3, wherein the internal projection is substantially annular and the plurality of ribs are substantially evenly spaced about a perimeter of the internal projection.
  • 5. The infusion set of claim 3, wherein the coupling device is solely coupled to the surface and the plurality of ribs.
  • 6. The infusion set of claim 5, wherein the coupling device further comprises an adhesive.
  • 7. The infusion set of claim 1, wherein the bore has a first diameter that is about equal to a second diameter of the fluid outlet.
  • 8. The infusion set of claim 1, wherein the infusion set is an insulin infusion set for use with an insulin infusion device.
  • 9. An infusion set for use with a fluid infusion device, comprising: a connector to fluidly couple the fluid infusion device to the infusion set;a mount having a distal end coupled to the connector and a proximal end, the mount including an internal projection defined within the mount from the distal end to the proximal end, the internal projection including a first end opposite a second end and having a bore that extends along an axis, the first end of the internal projection defined at the distal end and the second end of the internal projection defined at the proximal end of the mount, the proximal end including a plurality of ribs that extend from a surface of the proximal end to the second end of the internal projection, the plurality of ribs arranged to lie in a plane transverse to the axis;a fluid outlet coupled to at least a portion of the bore of the mount to be in fluid communication with the fluid infusion device through the connector; anda coupling device to couple the infusion set to a user, the coupling device coupled to the surface and each of the plurality of spaced apart ribs of the proximal end.
  • 10. The infusion set of claim 9, wherein the internal projection is surrounded at least partially by a recess defined through the surface of the proximal end, and each of the plurality of ribs span the recess.
  • 11. The infusion set of claim 10, wherein the plurality of ribs are substantially evenly spaced about a perimeter of the second end of the internal projection.
  • 12. The infusion set of claim 11, wherein the plurality of ribs are symmetric with respect to the axis.
  • 13. The infusion set of claim 10, wherein the internal projection is substantially annular and the plurality of ribs are substantially evenly spaced about a perimeter of the internal projection.
  • 14. The infusion set of claim 9, wherein the coupling device is solely coupled to the surface and the plurality of ribs.
  • 15. The infusion set of claim 14, wherein the coupling device further comprises an adhesive.
  • 16. The infusion set of claim 9, wherein the bore has a first diameter of about 0.8 millimeters.
US Referenced Citations (251)
Number Name Date Kind
3631847 Hobbs, II Jan 1972 A
4212738 Henne Jul 1980 A
4270532 Franetzki et al. Jun 1981 A
4282872 Franetzki et al. Aug 1981 A
4373527 Fischell Feb 1983 A
4395259 Prestele et al. Jul 1983 A
4433072 Pusineri et al. Feb 1984 A
4443218 DeCant, Jr. et al. Apr 1984 A
4494950 Fischell Jan 1985 A
4542532 McQuilkin Sep 1985 A
4550731 Batina et al. Nov 1985 A
4559037 Franetzki et al. Dec 1985 A
4562751 Nason et al. Jan 1986 A
4671288 Gough Jun 1987 A
4678408 Nason et al. Jul 1987 A
4685903 Cable et al. Aug 1987 A
4731051 Fischell Mar 1988 A
4731726 Allen, III Mar 1988 A
4781798 Gough Nov 1988 A
4803625 Fu et al. Feb 1989 A
4809697 Causey, III et al. Mar 1989 A
4826810 Aoki May 1989 A
4871351 Feingold Oct 1989 A
4898578 Rubalcaba, Jr. Feb 1990 A
5003298 Havel Mar 1991 A
5011468 Lundquist et al. Apr 1991 A
5019974 Beckers May 1991 A
5050612 Matsumura Sep 1991 A
5078683 Sancoff et al. Jan 1992 A
5080653 Voss et al. Jan 1992 A
5097122 Colman et al. Mar 1992 A
5100380 Epstein et al. Mar 1992 A
5101814 Palti Apr 1992 A
5108819 Heller et al. Apr 1992 A
5153827 Coutre et al. Oct 1992 A
5165407 Wilson et al. Nov 1992 A
5247434 Peterson et al. Sep 1993 A
5262035 Gregg et al. Nov 1993 A
5262305 Heller et al. Nov 1993 A
5264104 Gregg et al. Nov 1993 A
5264105 Gregg et al. Nov 1993 A
5284140 Allen et al. Feb 1994 A
5299571 Mastrototaro Apr 1994 A
5307263 Brown Apr 1994 A
5317506 Coutre et al. May 1994 A
5320725 Gregg et al. Jun 1994 A
5322063 Allen et al. Jun 1994 A
5338157 Blomquist Aug 1994 A
5339821 Fujimoto Aug 1994 A
5341291 Roizen et al. Aug 1994 A
5350411 Ryan et al. Sep 1994 A
5356786 Heller et al. Oct 1994 A
5357427 Langen et al. Oct 1994 A
5368562 Blomquist et al. Nov 1994 A
5370622 Livingston et al. Dec 1994 A
5371687 Holmes, II et al. Dec 1994 A
5376070 Purvis et al. Dec 1994 A
5390671 Lord et al. Feb 1995 A
5391250 Cheney, II et al. Feb 1995 A
5403700 Heller et al. Apr 1995 A
5411647 Johnson et al. May 1995 A
5445616 Kratoska et al. Aug 1995 A
5482473 Lord et al. Jan 1996 A
5485408 Blomquist Jan 1996 A
5497772 Schulman et al. Mar 1996 A
5505709 Funderburk et al. Apr 1996 A
5543326 Heller et al. Aug 1996 A
5551849 Christiansen Sep 1996 A
5569186 Lord et al. Oct 1996 A
5569187 Kaiser Oct 1996 A
5573506 Vasko Nov 1996 A
5582593 Hultman Dec 1996 A
5586553 Halili et al. Dec 1996 A
5593390 Castellano et al. Jan 1997 A
5593852 Heller et al. Jan 1997 A
5594638 Illiff Jan 1997 A
5609060 Dent Mar 1997 A
5626144 Tacklind et al. May 1997 A
5630710 Tune et al. May 1997 A
5643212 Coutre et al. Jul 1997 A
5660163 Schulman et al. Aug 1997 A
5660176 Iliff Aug 1997 A
5665065 Colman et al. Sep 1997 A
5665222 Heller et al. Sep 1997 A
5685844 Marttila Nov 1997 A
5687734 Dempsey et al. Nov 1997 A
5704366 Tacklind et al. Jan 1998 A
5750926 Schulman et al. May 1998 A
5754111 Garcia May 1998 A
5764159 Neftel Jun 1998 A
5772635 Dastur et al. Jun 1998 A
5779665 Mastrototaro et al. Jul 1998 A
5788669 Peterson Aug 1998 A
5791344 Schulman et al. Aug 1998 A
5800420 Gross et al. Sep 1998 A
5807336 Russo et al. Sep 1998 A
5814015 Gargano et al. Sep 1998 A
5822715 Worthington et al. Oct 1998 A
5832448 Brown Nov 1998 A
5840020 Heinonen et al. Nov 1998 A
5861018 Feierbach et al. Jan 1999 A
5868669 Iliff Feb 1999 A
5871465 Vasko Feb 1999 A
5879163 Brown et al. Mar 1999 A
5885245 Lynch et al. Mar 1999 A
5897493 Brown Apr 1999 A
5899855 Brown May 1999 A
5904708 Goedeke May 1999 A
5913310 Brown Jun 1999 A
5917346 Gord Jun 1999 A
5918603 Brown Jul 1999 A
5925021 Castellano et al. Jul 1999 A
5933136 Brown Aug 1999 A
5935099 Peterson et al. Aug 1999 A
5940801 Brown Aug 1999 A
5956501 Brown Sep 1999 A
5960403 Brown Sep 1999 A
5965380 Heller et al. Oct 1999 A
5972199 Heller et al. Oct 1999 A
5978236 Faberman et al. Nov 1999 A
5997476 Brown Dec 1999 A
5999848 Gord et al. Dec 1999 A
5999849 Gord et al. Dec 1999 A
6009339 Bentsen et al. Dec 1999 A
6032119 Brown et al. Feb 2000 A
6043437 Schulman et al. Mar 2000 A
6081736 Colvin et al. Jun 2000 A
6083710 Heller et al. Jul 2000 A
6088608 Schulman et al. Jul 2000 A
6101478 Brown Aug 2000 A
6103033 Say et al. Aug 2000 A
6119028 Schulman et al. Sep 2000 A
6120676 Heller et al. Sep 2000 A
6121009 Heller et al. Sep 2000 A
6134461 Say et al. Oct 2000 A
6143164 Heller et al. Nov 2000 A
6162611 Heller et al. Dec 2000 A
6175752 Say et al. Jan 2001 B1
6183412 Benkowski et al. Feb 2001 B1
6246992 Brown Jun 2001 B1
6259937 Schulman et al. Jul 2001 B1
6329161 Heller et al. Dec 2001 B1
6408330 DeLaHuerga Jun 2002 B1
6424847 Mastrototaro et al. Jul 2002 B1
6472122 Schulman et al. Oct 2002 B1
6484045 Holker et al. Nov 2002 B1
6484046 Say et al. Nov 2002 B1
6485465 Moberg et al. Nov 2002 B2
6503381 Gotoh et al. Jan 2003 B1
6514718 Heller et al. Feb 2003 B2
6544173 West et al. Apr 2003 B2
6553263 Meadows et al. Apr 2003 B1
6554798 Mann et al. Apr 2003 B1
6558320 Causey, III et al. May 2003 B1
6558351 Steil et al. May 2003 B1
6560741 Gerety et al. May 2003 B1
6565509 Say et al. May 2003 B1
6579690 Bonnecaze et al. Jun 2003 B1
6591125 Buse et al. Jul 2003 B1
6592745 Feldman et al. Jul 2003 B1
6605200 Mao et al. Aug 2003 B1
6605201 Mao et al. Aug 2003 B1
6607658 Heller et al. Aug 2003 B1
6616819 Liamos et al. Sep 2003 B1
6618934 Feldman et al. Sep 2003 B1
6623501 Heller et al. Sep 2003 B2
6641533 Causey, III et al. Nov 2003 B2
6654625 Say et al. Nov 2003 B1
6659980 Moberg et al. Dec 2003 B2
6671554 Gibson et al. Dec 2003 B2
6676816 Mao et al. Jan 2004 B2
6689265 Heller et al. Feb 2004 B2
6728576 Thompson et al. Apr 2004 B2
6733471 Ericson et al. May 2004 B1
6746582 Heller et al. Jun 2004 B2
6747556 Medema et al. Jun 2004 B2
6749740 Liamos et al. Jun 2004 B2
6752787 Causey, III et al. Jun 2004 B1
6809653 Mann et al. Oct 2004 B1
6817990 Yap et al. Nov 2004 B2
6881551 Heller et al. Apr 2005 B2
6892085 McIvor et al. May 2005 B2
6893545 Gotoh et al. May 2005 B2
6895263 Shin et al. May 2005 B2
6916159 Rush et al. Jul 2005 B2
6932584 Gray et al. Aug 2005 B2
6932894 Mao et al. Aug 2005 B2
6942518 Liamos et al. Sep 2005 B2
7153263 Carter et al. Dec 2006 B2
7153289 Vasko Dec 2006 B2
7396330 Banet et al. Jul 2008 B2
7621893 Moberg et al. Nov 2009 B2
7828764 Moberg et al. Nov 2010 B2
7905868 Moberg et al. Mar 2011 B2
20010044731 Coffman et al. Nov 2001 A1
20020013518 West et al. Jan 2002 A1
20020055857 Mault et al. May 2002 A1
20020082665 Haller et al. Jun 2002 A1
20020137997 Mastrototaro et al. Sep 2002 A1
20020161288 Shin et al. Oct 2002 A1
20030060765 Campbell et al. Mar 2003 A1
20030078560 Miller et al. Apr 2003 A1
20030088166 Say et al. May 2003 A1
20030144581 Conn et al. Jul 2003 A1
20030152823 Heller Aug 2003 A1
20030176183 Drucker et al. Sep 2003 A1
20030188427 Say et al. Oct 2003 A1
20030199744 Buse et al. Oct 2003 A1
20030208113 Mault et al. Nov 2003 A1
20030220552 Reghabi et al. Nov 2003 A1
20040061232 Shah et al. Apr 2004 A1
20040061234 Shah et al. Apr 2004 A1
20040064133 Miller et al. Apr 2004 A1
20040064156 Shah et al. Apr 2004 A1
20040073095 Causey, III et al. Apr 2004 A1
20040074785 Holker et al. Apr 2004 A1
20040093167 Braig et al. May 2004 A1
20040097796 Berman et al. May 2004 A1
20040102683 Khanuja et al. May 2004 A1
20040111017 Say et al. Jun 2004 A1
20040122353 Shahmirian et al. Jun 2004 A1
20040167465 Mihai et al. Aug 2004 A1
20040263354 Mann et al. Dec 2004 A1
20050038331 Silaski et al. Feb 2005 A1
20050038680 McMahon et al. Feb 2005 A1
20050113761 Faust et al. May 2005 A1
20050154271 Rasdal et al. Jul 2005 A1
20050192557 Brauker et al. Sep 2005 A1
20050234405 Dikeman et al. Oct 2005 A1
20060229694 Schulman et al. Oct 2006 A1
20060238333 Welch et al. Oct 2006 A1
20060293571 Bao et al. Dec 2006 A1
20070000828 Norman et al. Jan 2007 A1
20070088521 Shmueli et al. Apr 2007 A1
20070135866 Baker et al. Jun 2007 A1
20080154503 Wittenber et al. Jun 2008 A1
20080269687 Chong et al. Oct 2008 A1
20080281297 Pesach et al. Nov 2008 A1
20090081951 Erdmann et al. Mar 2009 A1
20090082635 Baldus et al. Mar 2009 A1
20090143763 Wyss et al. Jun 2009 A1
20090221971 Mejlhede et al. Sep 2009 A1
20090299290 Moberg Dec 2009 A1
20100030156 Beebe et al. Feb 2010 A1
20100256598 Mernoe et al. Oct 2010 A1
20110306935 Tanaka et al. Dec 2011 A1
20110313351 Kamen et al. Dec 2011 A1
20120209191 Gray et al. Aug 2012 A1
20130030342 Scheremet et al. Jan 2013 A1
20130218134 Tanaka et al. Aug 2013 A1
20130310754 Kutsch Nov 2013 A1
Foreign Referenced Citations (29)
Number Date Country
8619002 Aug 1986 DE
4329229 Mar 1995 DE
0319268 Nov 1988 EP
0806738 Nov 1997 EP
0880936 Dec 1998 EP
1338295 Aug 2003 EP
1631036 Mar 2006 EP
2218831 Nov 1989 GB
WO 9620745 Jul 1996 WO
WO 9636389 Nov 1996 WO
WO 9637246 Nov 1996 WO
WO 9721456 Jun 1997 WO
WO 9820439 May 1998 WO
WO 9824358 Jun 1998 WO
WO 9842407 Oct 1998 WO
WO 9849659 Nov 1998 WO
WO 9859487 Dec 1998 WO
WO 9908183 Feb 1999 WO
WO 9910801 Mar 1999 WO
WO 9918532 Apr 1999 WO
WO 9922236 May 1999 WO
WO 0010628 Mar 2000 WO
WO 0019887 Apr 2000 WO
WO 0048112 Aug 2000 WO
WO 02058537 Aug 2002 WO
WO 02076526 Oct 2002 WO
WO 03001329 Jan 2003 WO
WO 03094090 Nov 2003 WO
WO 2005065538 Jul 2005 WO
Non-Patent Literature Citations (92)
Entry
PCT Search Report (PCT/US02/03299), Oct. 31, 2002, Medtronic Minimed, Inc.
(Animas Corporation, 1999). Animas . . . bringing new life to insulin therapy.
Bode B W, et al. (1996). Reduction in Severe Hypoglycemia with Long-Term Continuous Subcutaneous Insulin Infusion in Type I Diabetes. Diabetes Care, vol. 19, No. 4, 324-327.
Boland E (1998). Teens Pumping it Up! Insulin Pump Therapy Guide for Adolescents. 2nd Edition.
Brackenridge B P (1992). Carbohydrate Gram Counting A Key to Accurate Mealtime Boluses in Intensive Diabetes Therapy. Practical Diabetology, vol. 11, No. 2, pp. 22-28.
Brackenridge, B P et al. (1995). Counting Carbohydrates How to Zero in on Good Control. MiniMed Technologies Inc.
Farkas-Hirsch R et al. (1994). Continuous Subcutaneous Insulin Infusion: A Review of the Past and Its Implementation for the Future. Diabetes Spectrum From Research to Practice, vol. 7, No. 2, pp. 80-84, 136-138.
Hirsch I B et al. (1990). Intensive Insulin Therapy for Treatment of Type I Diabetes. Diabetes Care, vol. 13, No. 12, pp. 1265-1283.
Kulkarni K et al. (1999). Carbohydrate Counting A Primer for Insulin Pump Users to Zero in on Good Control. MiniMed Inc.
Marcus A O et al. (1996). Insulin Pump Therapy Acceptable Alternative to Injection Therapy. Postgraduate Medicine, vol. 99, No. 3, pp. 125-142.
Reed J et al. (1996). Voice of the Diabetic, vol. 11, No. 3, pp. 1-38.
Skyler J S (1989). Continuous Subcutaneous Insulin Infusion [CSII] With External Devices: Current Status. Update in Drug Delivery Systems, Chapter 13, pp. 163-183. Futura Publishing Company.
Skyler J S et al. (1995). The Insulin Pump Therapy Book Insights from the Experts. MiniMed•Technologies.
Strowig S M (1993). Initiation and Management of Insulin Pump Therapy. The Diabetes Educator, vol. 19, No. 1, pp. 50-60.
Walsh J, et al. (1989). Pumping Insulin: The Art of Using an Insulin Pump. Published by MiniMed•Technologies.
(Intensive Diabetes Management, 1995). Insulin Infusion Pump Therapy. pp. 66-78.
Disetronic My Choice™ D-TRON™ Insulin Pump Reference Manual. (no date).
Disetronic H-TRON® plus Quick Start Manual. (no date).
Disetronic My Choice H-TRONplus Insulin Pump Reference Manual. (no date).
Disetronic H-TRON® plus Reference Manual. (no date).
(MiniMed, 1996). The MiniMed 506. 7 pages. Retrieved on Sep. 16, 2003 from the World Wide Web: http://web.archive.org/web/19961111054527/www.minimed.com/files/506—pic.htm.
(MiniMed, 1997). MiniMed 507 Specifications. 2 pages. Retrieved on Sep. 16, 2003 from the World Wide Web: http://web.archive.org/web/19970124234841/www.minimed.com/files/mmn075.htm.
(MiniMed, 1996). FAQ: The Practical Things . . . pp. 1-4. Retrieved on Sep. 16, 2003 from the World Wide Web: http://web.archive.org/web/19961111054546/www.minimed.com/files/faq—pract.htm.
(MiniMed, 1997). Wanted: a Few Good Belt Clips! 1 page. Retrieved on Sep. 16, 2003 from the World Wide Web: http://web.archive.org/web/19970124234559/www.minimed.com/files/mmn002.htm.
(MiniMed Technologies, 1994). MiniMed 506 Insulin Pump User's Guide.
(MiniMed Technologies, 1994). MiniMed™ Dosage Calculator Initial Meal Bolus Guidelines / MiniMed™ Dosage Calculator Initial Basal Rate Guidelines Percentage Method. 4 pages.
(MiniMed, 1996). MiniMed™ 507 Insulin Pump User's Guide.
(MiniMed, 1997). MiniMed™ 507 Insulin Pump User's Guide.
(MiniMed, 1998). MiniMed 507C Insulin Pump User's Guide.
(MiniMed International, 1998). MiniMed 507C Insulin Pump for those who appreciate the difference.
(MiniMed Inc., 1999). MiniMed 508 Flipchart Guide to Insulin Pump Therapy.
(MiniMed Inc., 1999). Insulin Pump Comparison / Pump Therapy Will Change Your Life.
(MiniMed, 2000). MiniMed® 508 User's Guide.
(MiniMed Inc., 2000). MiniMed® Now [I] Can Meal Bolus Calculator / MiniMed® Now [I] Can Correction Bolus Calculator.
(MiniMed Inc., 2000). Now [I] Can MiniMed Pump Therapy.
(MiniMed Inc., 2000). Now [I] Can MiniMed Diabetes Management.
(Medtronic MiniMed, 2002). The 508 Insulin Pump A Tradition of Excellence.
(Medtronic MiniMed, 2002). Medtronic MiniMed Meal Bolus Calculator and Correction Bolus Calculator. International Version.
Abel, P., et al., “Experience with an implantable glucose sensor as a prerequiste of an artificial beta cell,” Biomed. Biochim. Acta 43 (1984) 5, pp. 577-584.
Bindra, Dilbir S., et al., “Design and in Vitro Studies of a Needle-Type Glucose Sensor for a Subcutaneous Monitoring,” American Chemistry Society, 1991, 63, pp. 1692-1696.
Boguslavsky, Leonid, et al., “Applications of redox polymers in biosensors,” Sold State Ionics 60, 1993, pp. 189-197.
Geise, Robert J., et al., “Electropolymerized 1,3-diaminobenzene for the construction of a 1,1′-dimethylferrocene mediated glucose biosensor,” Analytica Chimica Acta, 281, 1993, pp. 467-473.
Gernet, S., et al., “A Planar Glucose Enzyme Electrode,” Sensors and Actuators, 17, 1989, pp. 537-540.
Gernet, S., et al., “Fabrication and Characterization of a Planar Electromechanical Cell and its Application as a Glucose Sensor,” Sensors and Actuators, 18, 1989, pp. 59-70.
Gorton, L., et al., “Amperometric Biosensors Based on an Apparent Direct Electron Transfer Between Electrodes and Immobilized Peroxiases,” Analyst, Aug. 1991, vol. 117, pp. 1235-1241.
Gorton, L., et al., “Amperometric Glucose Sensors Based on Immobilized Glucose-Oxidizing Enymes and Chemically Modified Electrodes,” Analytica Chimica Acta, 249, 1991, pp. 43-54.
Gough, D. A., et al., “Two-Dimensional Enzyme Electrode Sensor for Glucose,” Analytical Chemistry, vol. 57, No. 5, 1985, pp. 2351-2357.
Gregg, Brian A., et al., “Cross-Linked Redox Gels Containing Glucose Oxidase for Amperometric Biosensor Applications,” Analytical Chemistry, 62, pp. 258-263.
Gregg, Brian A., et al., “Redox Polymer Films Containing Enzymes. 1. A Redox-Conducting Epoxy Cement: Synthesis, Characterization, and Electrocatalytic Oxidation of Hydroquinone,” The Journal of Physical Chemistry, vol. 95, No. 15, 1991, pp. 5970-5975.
Hashiguchi, Yasuhiro, MD, et al., “Development of a Miniaturized Glucose Monitoring System by Combining a Needle-Type Glucose Sensor With Microdialysis Sampling Method,” Diabetes Care, vol. 17, No. 5, May 1994, pp. 387-389.
Heller, Adam, “Electrical Wiring of Redox Enzymes,” Acc. Chem. Res., vol. 23, No. 5, May 1990, pp. 128-134.
Jobst, Gerhard, et al., “Thin-Film Microbiosensors for Glucose-Lactate Monitoring,” Analytical Chemistry, vol. 68, No. 18, Sep. 15, 1996, pp. 3173-3179.
Johnson, K.W., et al., “In vivo evaluation of an electroenzymatic glucose sensor implanted in subcutaneous tissue,” Biosensors & Bioelectronics, 7, 1992, pp. 709-714.
Jönsson, G., et al., “An Electromechanical Sensor for Hydrogen Peroxide Based on Peroxidase Adsorbed on a Spectrographic Graphite Electrode,” Electroanalysis, 1989, pp. 465-468.
Kanapieniene, J. J., et al., “Miniature Glucose Biosensor with Extended Linearity,” Sensors and Actuators, B. 10, 1992, pp. 37-40.
Kawamori, Ryuzo, et al., “Perfect Normalization of Excessive Glucagon Responses to Intraveneous Arginine in Human Diabetes Mellitus With the Artificial Beta-Cell,” Diabetes vol. 29, Sep. 1980, pp. 762-765.
Kimura, J., et al., “An Immobilized Enzyme Membrane Fabrication Method,” Biosensors 4, 1988, pp. 41-52.
Koudelka, M., et al., “In-vivo Behaviour of Hypodermically Implanted Microfabricated Glucose Sensors,” Biosensors & Bioelectronics 6, 1991, pp. 31-36.
Koudelka, M., et al., “Planar Amperometric Enzyme-Based Glucose Microelectrode,” Sensors & Actuators, 18, 1989, pp. 157-165.
Mastrototaro, John J., et al., “An electroenzymatic glucose sensor fabricated on a flexible substrate,” Sensors & Actuators, B. 5, 1991, pp. 139-144.
Mastrototaro, John J., et al., “An Electroenzymatic Sensor Capable of 72 Hour Continuous Monitoring of Subcutaneous Glucose,” 14th Annual International Diabetes Federation Congress, Washington D.C., Jun. 23-28, 1991.
McKean, Brian D., et al., “A Telemetry-Instrumentation System for Chronically Implanted Glucose and Oxygen Sensors,” IEEE Transactions on Biomedical Engineering, Vo. 35, No. 7, Jul. 1988, pp. 526-532.
Monroe, D., “Novel Implantable Glucose Sensors,” ACL, Dec. 1989, pp. 8-16.
Morff, Robert J., et al., “Microfabrication of Reproducible, Economical, Electroenzymatic Glucose Sensors,” Annuaal International Conference of teh IEEE Engineering in Medicine and Biology Society, Vo. 12, No. 2, 1990, pp. 483-484.
Moussy, Francis, et al., “Performance of Subcutaneously Implanted Needle-Type Glucose Sensors Employing a Novel Trilayer Coating,” Analytical Chemistry, vol. 65, No. 15, Aug. 1, 1993, pp. 2072-2077.
Nakamoto, S., et al., “A Lift-Off Method for Patterning Enzyme-Immobilized Membranes in Multi-Biosensors,” Sensors and Actuators 13, 1988, pp. 165-172.
Nishida, Kenro, et al., “Clinical applications of teh wearable artifical endocrine pancreas with the newly designed needle-type glucose sensor,” Elsevier Sciences B.V., 1994, pp. 353-358.
Nishida, Kenro, et al., “Development of a ferrocene-mediated needle-type glucose sensor covereed with newly designd biocompatible membrane, 2-methacryloyloxyethylphosphorylcholine -co-n-butyl nethacrylate,” Medical Progress Through Technology, vol. 21, 1995, pp. 91-103.
Poitout, V., et al., “A glucose monitoring system for on line estimation oin man of blood glucose concentration using a miniaturized glucose sensor implanted in the subcutaneous tissue adn a wearable control unit,” Diabetologia, vol. 36, 1991, pp. 658-663.
Reach, G., “A Method for Evaluating in vivo the Functional Characteristics of Glucose Sensors,” Biosensors 2, 1986, pp. 211-220.
Shaw, G. W., et al., “In vitro testing of a simply constructed, highly stable glucose sensor suitable for implantation in diabetic patients,” Biosensors & Bioelectronics 6, 1991, pp. 401-406.
Shichiri, M., “A Needle-Type Glucose Sensor—A Valuable Tool Not Only for a Self-Blood Glucose Monitoring but for a Wearable Artifiical Pancreas,” Life Support Systems Proceedings, XI Annual Meeting ESAO, Alpbach-Innsbruck, Austria, Sep. 1984, pp. 7-9.
Shichiri, Motoaki, et al., “An artificial endocrine pancreas—problems awaiting solution for long-term clinical applications of a glucose sensor,” Frontiers Med. Biol. Engng., 1991, vol. 3, No. 4, pp. 283-292.
Shichiri, Motoaki, et al., “Closed-Loop Glycemic Control with a Wearable Artificial Endocrine Pancreas—Variations in Daily Insulin Requirements to Glycemic Response,” Diabetes, vol. 33, Dec. 1984, pp. 1200-1202.
Shichiri, Motoaki, et al., “Glycaemic Control in a Pacreatectomized Dogs with a Wearable Artificial Endocrine Pancreas,” Diabetologia, vol. 24, 1983, pp. 179-184.
Shichiri, M., et al., “In Vivo Characteristics of Needle-Type Glucose Sensor—Measurements of Subcutaneous Glucose Concentrations in Human Volunteers,” Hormone and Metabolic Research, Supplement Series vol. No. 20, 1988, pp. 17-20.
Shichiri, M., at al., “Membrane design for extending the long-life of an implantable glucose sensor,” Diab. Nutr. Metab., vol. 2, No. 4, 1989, pp. 309-313.
Shichiri, Motoaki, et al., “Normalization of the Paradoxic Secretion of Glucagon in Diabetes Who Were Controlled by the Artificial Beta Cell,” Diabetes, vol. 28, Apr. 1979, pp. 272-275.
Shichiri, Motoaki, et al., “Telemetry Glucose Monitoring Device with Needle-Type Glucose Sensor: A useful Tool for Blood Glucose Monitoring in Diabetic Individuals,” Diabetes Care, vol. 9, No. 3, May-Jun. 1986, pp. 298-301.
Shichiri, Motoaki, et al., “Wearable Artificial Endocrine Pancreas with Needle-Type Glucose Sensor,” The Lancet, Nov. 20, 1982, pp. 1129-1131.
Shichiri, Motoaki, at al., “The Wearable Artificial Endocrine Pancreas with a Needle-Type Glucose Sensor: Perfect Glycemic Control in Ambulatory Diabetes,” Acta Paediatr Jpn 1984, vol. 26, pp. 359-370.
Shinkai, Seiji, “Molecular Recognitiion of Mono- and Di-saccharides by Phenylboronic Acids in Solvent Extraction and as a Monolayer,” J. Chem. Soc., Chem. Commun., 1991, pp. 1039-1041.
Shults, Mark C., “A Telemetry-Instrumentation System for Monitoring Multiple Subcutaneously Implanted Glucose Sensors,” IEEE Transactions on Biomedical Engineering, vol. 41, No. 10, Oct. 1994, pp. 937-942.
Sternberg, Robert, et al., “Study and Development of Multilayer Needle-type Enzyme-based Glucose Microsensors,” Biosensors, vol. 4, 1988, pp. 27-40.
Tamiya, E., et al., “Micro Glucose Sensors using Electron Mediators Immobilized on a Polypyrrole-Modified Electrode,” Sensors and Actuators, vol. 18, 1989, pp. 297-307.
Tsukagoshi, Kazuhiko, et al., “Specific Complexation with Mono- and Disaccharides that can be Detected by Circular Dichroism,” J. Org. Chem., vol. 56, 1991, pp. 4089-4091.
Urban, G., et al., “Miniaturized multi-enzyme biosensors integrated with pH sensors on flexible polymer carriers for in vivo applciations,” Biosensors & Bioelectronics, vol. 7, 1992, pp. 733-739.
Ubran, G., et al., “Miniaturized thin-film biosensors using covalently immobilized glucose oxidase,” Biosensors & Bioelectronics, vol. 6, 1991, pp. 555-562.
Velho, G., et al., “In vivo calibration of a subcutaneous glucose sensor for determination of subcutaneous glucose kinetics,” Diab. Nutr. Metab., vol. 3, 1988, pp. 227-233.
Wang, Joseph, et al., “Needle-Type Dual Microsensor for the Simultaneous Monitoring of Glucose and Insulin,” Analytical Chemistry, vol. 73, 2001, pp. 844-847.
Yamasaki, Yoshimitsu, et al., “Direct Measurement of Whole Blood Glucose by a Needle-Type Sensor,” Clinics Chimica Acta, vol. 93, 1989, pp. 93-98.
Yokoyama, K., “Integrated Biosensor for Glucose and Galactose,” Analytics Chimica Acta, vol. 218, 1989, pp. 137-142.
Related Publications (1)
Number Date Country
20140309593 A1 Oct 2014 US